Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the letter from the then Secretary of State for Health and Social Care on 6 September to Gemma Peters, Chief Executive of Blood Cancer UK, which states that “proceeding to patient access [to Evusheld is] considered to outweigh the risks of not providing this treatment in the current pandemic context”, what are the risks of not providing Evusheld.

The decision not to procure Evusheld at this present time through emergency routes is based on independent clinical advice by the multi-agency initiative RAPID C-19 and a national expert policy working group. Evusheld has now been referred to the National Institute for Health and Care Excellence for further evaluation.